A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Recruiting now · Phase 1
Conditions studied: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
In brief
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Key facts
- Study ID
- NCT04678648
- Run by
- RasCal Therapeutics, Inc.
- People needed
- 134
- Starts
- 2021-03-03
- Expected to finish
- 2027-01-30
- Last updated by the study team
- 2026-06-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology — Los Angeles, California, United States (enrolling)
- Sarah Cannon, SCRI Oncology Partners - Health One — Denver, Colorado, United States (enrolling)
- Sarah Cannon, SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.